Clinical trial
A Prospective, One-arm and Open Clinical Study to Assess Safety and Efficacy of Anti-CD38 Antibody in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
NCT05983952 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, One-arm and Open Clinical Study to Assess Safety and Efficacy of Anti-CD38 Antibody in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- August 1, 2023
- Completion date
- August 31, 2025
- Enrollment
- 10 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.